Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02897232 · ClinicalTrials.gov registry record
Community and Physician Perspectives Regarding Male Youth Human Papillomavirus (HPV) Disease and Vaccination
A clinical trial, sponsored by Louisiana State University Health Sciences Center Shreveport.
- Completed
- Registry status
- 386
- Enrollment target
NCT02897232: Completed study, sponsored by Louisiana State University Health Sciences Center Shreveport.
NCT02897232 is a clinical trial that has completed, run by Louisiana State University Health Sciences Center Shreveport. The registered enrollment target is 386 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02897232 has completed, sponsored by Louisiana State University Health Sciences Center Shreveport.
- COMPLETED
- Registry status
- 386 participants
- Enrollment target
Study Summary
This is a minimal risk, anonymous, convenience sample, social behavioral study using qualitative descriptive survey methods. It is to ascertain community member, physician, resident and medical student perspectives regarding Human Papillomavirus (HPV) infection, associated diseases and to identify barriers which prevent these groups from ensuring that males 9-26 receive the three-shot vaccine series to prevent HPV infection. The research is focused on these questions: Do community members understand the ease of transmission of the HPV virus in males 9-26? Do community members, physicians, residents and medical students have knowledge of the associated diseases that may occur with the HPV virus infection in males age 9-26? Do community members, physicians, residents and medical students know the ages in which males should receive the HPV vaccine three-shot series? What barriers prevent community members and physicians, residents and medical students from ensuring that males 9-26 receive the three-shot vaccine series to prevent HPV infection?
Primary Outcome
What are the barriers which prevent community members and physicians, residents and medical students from ensuring that males age 9-26 are vaccinated with the HPV three-shot vaccination.
Interventions
- OTHER Survey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 386 participants |
| Start Date | 2016-07 |
| Est. Completion | 2020-04 |
What the finished NCT02897232 record still lists
NCT02897232 is an observational study that tracks outcomes without assigning an intervention. The registered 386 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Survey is the first listed.
NCT02897232 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02897232 about?
NCT02897232 is a clinical study titled "Community and Physician Perspectives Regarding Male Youth Human Papillomavirus (HPV) Disease and Vaccination". This is a minimal risk, anonymous, convenience sample, social behavioral study using qualitative descriptive survey methods. It is to ascertain community member, physician, resident and medical student perspectives regarding Human Papillomavirus (HPV) infection, associated diseases and to identify b...
What is the current status of trial NCT02897232?
This trial is currently completed. The enrollment target is 386 participants. The study started on 2016-07. Estimated completion is 2020-04.
What interventions are being tested in trial NCT02897232?
The interventions under investigation include: Survey (OTHER).
Who is sponsoring clinical trial NCT02897232?
This trial is sponsored by Louisiana State University Health Sciences Center Shreveport, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645107 · 386 participants · Phase 3
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- NCT05896189 · 386 participants · NA
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
- NCT06686121 · 386 participants · Phase 3
Improving Mobility After Revascularization in Peripheral Artery Disease
- NCT07424547 · 386 participants · Phase 1
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia